Victory Square Technologies Portfolio Company’s Leishmaniasis Rapid Test Receives Brazilian MAPA Approval for Sale & Use for the Country of Brazil and Enters into a Sales & Distribution Contract with Ecodiagnostica of Brazil

• Victory Square Health’s Leishmaniasis Rapid Test received Brazilian MAPA approval for sale and usage in Brazil and export to Mercosur Countries in Central and South America
  

• Leishmaniasis is a parasitic disease that affects humans and canines in Southern Europe, Central America, South America, Mexico and the Middle East

• About 4 to 12 million people are currently infected^[4][5] in some 98 countries.^[3] About 2 million new cases^[3] occur annually that if undetected and untreated can cause disabilities and death.

• About 200 million people in Asia, Africa, South and Central America, and southern Europe live in areas where the disease is common.^[3][11]

• The Company has already received a sales order from Ecodiagnostica of Brazil for the newly approved Leishmaniasis Rapid Test
  

VANCOUVER, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – a portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) announced today that it was granted approval by the Brazilian Ministry of Agriculture, Livestock, and Food Supply (MAPA) to commence marketing, sales and distribution for its Leishmaniasis Rapid Test in Brazil and export to Mercosur Countries (Argentina, Paraguay, Uruguay, and Venezuela) in Central and South America. The Company entered into a sales & distribution contract and formal partnership for the Leishmaniasis test with Ecodiagnostica of Brazil.

Leishmaniasis, is one of the world’s most neglected diseases and VS Health is strategically positioned to address this unmet need for quick and reliable testing.

Leishmaniasis is a parasitic disease that affects humans and canines in Southern Europe, Central America, South America, Mexico and the Middle East. About 4 to 12 million people are currently infected^[4][5] in some 98 countries.^[3] About 2 million new cases^[3] occur annually that if undetected and untreated can cause disabilities and death. About 200 million people in Asia, Africa, South and Central America, and southern Europe live in areas where the disease is common.^[3][11]

VS Health has developed and validated the clinical performance of its Leishmaniasis diagnostic test with a results that exceeds currently available tests with greater sensitivity and specificity in correctly diagnosing Leishmaniasis both in humans and canines with a sensitivity of 93.2% and specificity of a leading 91.3%.

The Company is pleased to have entered into a partnership, sales and distribution contract with Ecodiagnostica of Brazil for the sale of the Leishmaniasis test for South America. Ecodiagnostica (http://ecodiagnostica.com.br) manufactures and distributes products for the market of human diagnosis, veterinary, and food safety. Founded in 2012, Ecodiagnostica is based in Nova Lima, Brazil and has extensive sales and distribution networks across South America and beyond. Ecodiagnostica has placed an initial order of the VSH Leishmaniasis test at time of release.

“I am very pleased to announce our latest approval for another one of our tests in partnership with Ecodiagnostica. Our Leishmaniasis test is just one of many tests currently approved or in our development pipeline. Our global distribution and sales network has grown exponentially with our numerous approvals of our Safetest Covid-19 testing products. These new avenues and new partnership agreements will provide this test and others with easy access to key markets,” said Felipe Peixoto, CEO of Victory Square Health.

VS Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes. Its first product, the Leishmaniasis Rapid Test, was developed in partnership with the UFMG, Federal University of Minas Gerais. Safetest took advantage of its expertise in the subject to develop other antibody-based tests and a robust R&D pipelines of diagnostic kits for Hansen’s Disease, Brucellosis, HTLV and Blood samples screening tests.

Disclaimer:

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time

Check out VictorySquare.com and sign up to VST's official newsletter at www.VictorySquare.com/newsletter.

Reference (1)
WHO Expert Committee. Control of the leishmaniasis: Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 2010; 22-26 March. WHO Technical Report Series; 949:1-186. Available from: http://apps.who.int/iris/bitstream/10665/44412/1/WHO_TRS_949_eng.pdf

Reference (2)
PARASITOLOGY - CHAPTER TWO BLOOD AND TISSUE PROTOZOA PART 1 TRYPANOSOMIASIS AND LEISHMANIASIS
Dr Abdul Ghaffar Professor Emeritus University of South Carolina http://www.microbiologybook.org

On behalf of the board,

Shafin Diamond Tejani
Chief Executive Officer
Victory Square Technologies

For further information about the Company, please contact:

Investor Relations Contact – Alex Tzilios
Email: alexandros@victorysquare.com
Telephone: 778-867-0482

Media Relations Contact – Howard Blank, Director
Email: howard@victorysquare.com
Telephone: 604-928-6066

ABOUT VICTORY SQUARE TECHNOLOGIES INC.

Victory Square (VST) builds, acquires and invests in promising startups, then provides the senior leadership and resources needed to fast-track growth. The result: rapid scale-up and monetization, with a solid track record of public and private exits.

VST's sweet spot is the cutting-edge tech that's shaping the 4th Industrial Revolution. Our portfolio consists of 20 global companies using AI, VR/AR and blockchain to disrupt sectors as diverse as fintech, insurance, health and gaming.

What we do differently for startups
VST isn't just another investor. With real skin in the game, we're committed to ensuring each company in our portfolio succeeds. Our secret sauce starts with selecting startups that have real solutions, not just ideas. We pair you with senior talent in product, engineering, customer acquisition and more. Then we let you do what you do best — build, innovate and disrupt. In 24-36 months, you'll scale and be ready to monetize.

What we do differently for investors
VST is a publicly-traded company headquartered in Vancouver, Canada, and listed on the Canadian Securities Exchange (VST), Frankfurt Exchange (6F6) and the OTCQX (VSQTF).

For investors, we offer early-stage access to the next unicorns before they're unicorns.

Our portfolio represents a uniquely liquid and secure way for investors to get access to the latest cutting-edge technologies. Because we focus on market-ready solutions that scale quickly, we're able to provide strong and stable returns while also tapping into emerging global trends with big upsides. For more information, please visit www.victorysquare.com.

Forward Looking Statement

This news release contains “forward-looking information” within the meaning of applicable securities laws relating to the outlook of the business of Victory Square, including, without limitation, statements relating to future performance, execution of business strategy, future growth, business prospects and opportunities of Victory Square and its related subsidiaries, including Victory Square Health Inc., and other factors beyond our control. Such forward-looking statements may, without limitation, be preceded by, followed by, or include words such as “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans”, “continues”, “project”, “potential”, “possible”, “contemplate”, “seek”, “goal”, or similar expressions, or may employ such future or conditional verbs as “may”, “might”, “will”, “could”, “should” or “would”, or may otherwise be indicated as forward-looking statements by grammatical construction, phrasing or context. All statements other than statements of historical facts contained in this news release are forward-looking statements. Forward-looking information is based on certain key expectations and assumptions made by the management of Victory Square. Although Victory Square believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on them because Victory Square can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements contained in this news release are made as of the date of this news release. Victory Square disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.